M&A

News

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, w

News

Taisho says $5bn management buyout will rev up business

Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi

News

Roche makes obesity play with $2.7bn deal to buy Carmot

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapie

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

News

Boehringer buys cancer immunotherapy firm T3 for $507m

Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.

News

MSD reaches $610m deal to buy lysosome biotech Caraway

MSD has agreed to pay up to $610 million to acquire Caraway Therapeutics, a Cambridge, Massachusetts biotech focusing on neurodegenerative disorders and rare diseases.

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

Taisho says $5bn management buyout will rev up business

Roche makes obesity play with $2.7bn deal to buy Carmot

AbbVie agrees $10.1bn deal to buy ImmunoGen

Boehringer buys cancer immunotherapy firm T3 for $507m

MSD reaches $610m deal to buy lysosome biotech Caraway

Are Makary's priority review vouchers about to be canned?

Securing your ROI: Turning post-acquisition integration into...

M&A

Editor's Picks